NCT05220410

The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Sheppard Pratt Health System · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study aims to explore the safety and tolerability of a single dose of psilocybin (25mg) administered under supportive conditions to adult participants with TRD and chronic suicidal ideation

Conditions

• Treatment Resistant Depression
• Suicidal Ideation

Interventions

Type	Name	Description
DRUG	Psilocybin	Open-Label

Timeline

• Start date: 2022-03-28
• Primary completion: 2025-05-12
• Completion: 2025-05-12
• First posted: 2022-02-02
• Last updated: 2025-12-24

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study